Agilent Technologies Inc. has announced plans to split into two separate companies. One part will focus on life sciences, diagnostics and applied markets (LDA), which will retain the Agilent name whilst the other will be made up of the company’s current portfolio of electronic measurement (EM) products. The company has yet to reveal the name of this entity.
Agilent has evolved into two distinct investment and business opportunities, and we are creating two separate and strategically focused enterprises to allow each to maximise its growth and success,” said William Sullivan, Agilent President and CEO.
The company hopes to gain a greater, separate management focus on the two divisions.
It advises the LDA division will be able to devote resources to the higher-growth LDA business, while reducing exposure to the more cyclical EM industry.
The EM company will now also be able to devote resources to its own growth that were previously used to capitalise LDA.
This move will enable the “new Agilent” to focus on life sciences, diagnostics and applied markets, growth opportunities in emerging markets, molecular diagnostics and clinical markets, and significant margin-expansion opportunities.
The new EM company will focus on electronic measurement, with a position in major markets including communications; aerospace and defense; and industrial, computers and semiconductors.
Agilent Technologies
